Functions and inhibition of BET bromodomains in pathogenic fungi

被引：0
|
作者：
Sayou, Camille [1 ]
Govin, Jérôme [1 ]
机构：
[1] Inserm U1209, CNRS UMR 5309, Univ. Grenoble Alpes, Institute for Advanced Biosciences, Grenoble, France
来源：
Current Opinion in Green and Sustainable Chemistry | 2022年 / 34卷
关键词：
Antifungals - BET protein - Biological functions - Bromodomain - Chromatin - Drug compounds - Fungal infection - Fungal pathogen - Pathogenic fungi - Protein family;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Invasive fungal infections are a major public health problem. While therapeutic options remain very limited, new antifungal strategies are urgently needed. Bromodomains (BDs) of the BET protein family are chromatin-interacting modules with important biological functions. Human BET BDs can be inhibited by drug compounds, with clinical potential in oncology and inflammatory diseases. Here we review current knowledge of fungal BET BDs. We list their roles in chromatin signalling and present recent evidence for their selective inhibition. Finally, we discuss the possibility of using fungal BET BDs as therapeutic targets for future antifungal drug development. © 2022 Elsevier B.V.
引用
收藏
相关论文
共 50 条
  • [1] Functions and inhibition of BET bromodomains in pathogenic fungi
    Sayou, Camille
    Govin, Jerome
    CURRENT OPINION IN GREEN AND SUSTAINABLE CHEMISTRY, 2022, 34
  • [2] Selective inhibition of BET bromodomains
    Panagis Filippakopoulos
    Jun Qi
    Sarah Picaud
    Yao Shen
    William B. Smith
    Oleg Fedorov
    Elizabeth M. Morse
    Tracey Keates
    Tyler T. Hickman
    Ildiko Felletar
    Martin Philpott
    Shonagh Munro
    Michael R. McKeown
    Yuchuan Wang
    Amanda L. Christie
    Nathan West
    Michael J. Cameron
    Brian Schwartz
    Tom D. Heightman
    Nicholas La Thangue
    Christopher A. French
    Olaf Wiest
    Andrew L. Kung
    Stefan Knapp
    James E. Bradner
    Nature, 2010, 468 : 1067 - 1073
  • [3] Selective inhibition of BET bromodomains
    Filippakopoulos, Panagis
    Qi, Jun
    Picaud, Sarah
    Shen, Yao
    Smith, William B.
    Fedorov, Oleg
    Morse, Elizabeth M.
    Keates, Tracey
    Hickman, Tyler T.
    Felletar, Ildiko
    Philpott, Martin
    Munro, Shonagh
    McKeown, Michael R.
    Wang, Yuchuan
    Christie, Amanda L.
    West, Nathan
    Cameron, Michael J.
    Schwartz, Brian
    Heightman, Tom D.
    La Thangue, Nicholas
    French, Christopher A.
    Wiest, Olaf
    Kung, Andrew L.
    Knapp, Stefan
    Bradner, James E.
    NATURE, 2010, 468 (7327) : 1067 - 1073
  • [4] BET bromodomains' functions in bone-related pathologies
    Jacques, Camille
    Lavaud, Melanie
    Georges, Steven
    Tesfaye, Robel
    Baud'huin, Marc
    Lamoureux, Francois
    Ory, Benjamin
    EPIGENOMICS, 2020, 12 (02) : 127 - 144
  • [5] Inhibition of BET bromodomains alleviates inflammation in human RPE cells
    Hytti, M.
    Tokarz, P.
    Maatta, E.
    Piippo, N.
    Korhonen, E.
    Suuronen, T.
    Honkakoski, P.
    Kaarniranta, K.
    Lahtela-Kakkonen, M.
    Kauppinen, A.
    BIOCHEMICAL PHARMACOLOGY, 2016, 110 : 71 - 79
  • [6] Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
    Fu, Lei-lei
    Tian, Mao
    Li, Xiang
    Li, Jing-jing
    Huang, Jian
    Ouyang, Liang
    Zhang, Yonghui
    Liu, Bo
    ONCOTARGET, 2015, 6 (08) : 5501 - 5516
  • [7] Methylpyrrole inhibitors of BET bromodomains
    Hasvold, Lisa A.
    Sheppard, George S.
    Wang, Le
    Fidanze, Steven D.
    Liu, Dachun
    Pratt, John K.
    Mantei, Robert A.
    Wada, Carol K.
    Hubbard, Robbert
    Shen, Yu
    Lin, Xiaoyu
    Huang, Xiaoli
    Warder, Scott E.
    Wilcox, Denise
    Li, Leiming
    Buchanan, F. Greg
    Smithee, Lauren
    Albert, Daniel H.
    Magoc, Terrance J.
    Park, Chang H.
    Petros, Andrew M.
    Panchal, Sanjay C.
    Sun, Chaohong
    Kovar, Peter
    Soni, Nirupama B.
    Elmore, Steven W.
    Kati, Warren M.
    McDaniel, Keith F.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (10) : 2225 - 2233
  • [8] Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains
    Stuhlmiller, Timothy J.
    Miller, Samantha M.
    Johnson, Gary L.
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (01):
  • [9] Optimizing in vivo probes for the BET bromodomains
    Jennings, Laura E.
    Hewings, David S.
    Humphreys, Philip G.
    Brennan, Paul E.
    Conway, Stuart J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [10] Targeting BET bromodomains for cancer treatment
    Jung, Marie
    Gelato, Kathy A.
    Fernandez-Montalvan, Amaury
    Siegel, Stephan
    Haendler, Bernard
    EPIGENOMICS, 2015, 7 (03) : 487 - 501
12345